Minprog (Alprostadil)

Alprostadil, the active ingredient in Minprog, is a Prostaglandin E1 analog presented as a sterile injectable solution for intraarterial and intravenous use. It improves blood flow in peripheral arterial disease, coronary artery disease, and erectile dysfunction in adult patients by inducing smooth‑muscle relaxation and inhibiting platelet aggregation.

GNH USA supplies Minprog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant sourcing for global healthcare providers with reliable logistics and support.

Alprostadil is used as a vasodilator in several vascular conditions.

- Peripheral arterial disease: enhances limb perfusion and reduces ischemic symptoms. - Coronary artery disease: improves myocardial blood flow and may relieve angina. - Erectile dysfunction: facilitates penile erection by increasing blood flow to the corpora cavernosa.

Alprostadil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Pain at injection site - Flushing - Headache - Nausea

Serious or Rare Side Effects: - Priapism (prolonged erection) - Severe hypotension - Allergic reactions (anaphylaxis)

Before using Minprog, clinicians should consider several safety measures.

- Assess cardiovascular status: evaluate blood pressure and cardiac function before administration. - Avoid use in patients with severe hypotension: may exacerbate low blood pressure. - Monitor for priapism: discontinue if erection persists >4 hours. - Use with caution in patients on anticoagulants: increased bleeding risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Alprostadil can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): additive bleeding risk. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause severe hypotension. - Alpha‑blockers: risk of excessive vasodilation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt vasodilatory response. - Calcium channel blockers: possible additive blood pressure effects. - Nitroglycerin: monitor for excessive hypotension.